{
    "nctId": "NCT00243503",
    "briefTitle": "Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Percentage of Participants With Overall Confirmed Objective Disease Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease.\n* HER2 positive disease (3+ by immunohistochemistry \\[IHC\\] or FISH-positive)\n* Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted.\n\nExclusion Criteria:\n\n* Prior treatment with \\>1 regimen of cytotoxic therapy in the advanced disease setting. Adjuvant chemotherapy is permitted\n* Prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions.\n* Prior treatment on a SU11248 clinical trial.\n* Uncontrolled brain metastases.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}